Using neutrophil biomarkers to prevent abnormal bone growth after injuries
Neutrophil Biomarker and neutrophil targeted therapy to predict and prevent heterotopic ossification
['FUNDING_OTHER'] · UT SOUTHWESTERN MEDICAL CENTER · NIH-10900159
This study is looking at how to prevent unwanted bone growth in soft tissues after injuries like hip surgery, by finding specific markers in the immune system that can help identify patients who might be at risk, so we can create better treatments for them.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UT SOUTHWESTERN MEDICAL CENTER (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-10900159 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding and preventing heterotopic ossification (HO), which is the abnormal formation of bone in soft tissues following injuries such as hip surgery or severe trauma. The study aims to identify specific biomarkers related to neutrophils, a type of immune cell, that can predict which patients are at higher risk for developing HO. By targeting inflammation and developing a therapy based on these biomarkers, the research seeks to improve treatment protocols and outcomes for affected patients. The approach includes analyzing patient data and immune responses to create a more effective intervention strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients who have undergone hip arthroplasty, experienced musculoskeletal trauma, or suffered burns, particularly those with high-energy injuries.
Not a fit: Patients who have not experienced significant trauma or surgical interventions that could lead to heterotopic ossification may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prevention strategies for heterotopic ossification, improving recovery and functional capacity for patients after severe injuries.
How similar studies have performed: Previous research has shown promise in using biomarkers to guide treatment in similar inflammatory conditions, suggesting potential for success in this novel approach.
Where this research is happening
DALLAS, UNITED STATES
- UT SOUTHWESTERN MEDICAL CENTER — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEVI, BENJAMIN — UT SOUTHWESTERN MEDICAL CENTER
- Study coordinator: LEVI, BENJAMIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.